349 related articles for article (PubMed ID: 31775673)
21. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
22. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
[TBL] [Abstract][Full Text] [Related]
23. Update on second primary malignancies in multiple myeloma: a focused review.
Landgren O; Mailankody S
Leukemia; 2014 Jul; 28(7):1423-6. PubMed ID: 24418993
[TBL] [Abstract][Full Text] [Related]
24. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
26. A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Nair R; Gheith S; Popescu D; Agostino NM
Int J Clin Exp Pathol; 2014; 7(5):2683-9. PubMed ID: 24966987
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
28. Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.
Schoenbeck KL; Wildes TM
Clin Interv Aging; 2020; 15():619-633. PubMed ID: 32440105
[TBL] [Abstract][Full Text] [Related]
29. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
30. Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Gonzalez MM; Kidd L; Quesada J; Nguyen N; Chen L
Ann Clin Lab Sci; 2013; 43(2):176-80. PubMed ID: 23694793
[TBL] [Abstract][Full Text] [Related]
31. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Milrod CJ; Blevins F; Hughes D; Lerner A; Sarosiek S; Sanchorawala V; Sloan JM
Blood; 2021 May; 137(21):2987-2989. PubMed ID: 33728443
[No Abstract] [Full Text] [Related]
32. Second primary malignancies and myeloma therapy: fad or fact?
Usmani SZ
Oncotarget; 2012 Sep; 3(9):915-6. PubMed ID: 22989934
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
34. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
35. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Gertz MA; Terpos E; Dispenzieri A; Kumar S; Shah RA; Orlowski R; Kastritis E; Dimopoulos MA; Shah J
Leuk Lymphoma; 2015 Jun; 56(6):1723-6. PubMed ID: 25284489
[TBL] [Abstract][Full Text] [Related]
36. B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.
Arribas I; Maluquer C; Pomares H; Carro I; Baca C; Bosch A; Arévalo CE; Montané C; Ribes-Amorós J; Zamora L; Granada I; Gamundi E; Arnan M; Sureda A
Leuk Lymphoma; 2023 Oct; 64(10):1701-1705. PubMed ID: 37455651
[No Abstract] [Full Text] [Related]
37. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
38. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
39. Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.
Fracchiolla NS; Iurlo A; Ferla V; Fattizzo B; Freyrie A; Reda G; Cortelezzi A
Clin Lab; 2017 Sep; 63(9):1513-1517. PubMed ID: 28879716
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
